Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US
JAMA Oncology · 01.01.2025 · 11 (1) · 70
DOI: 10.1001/jamaoncol.2024.5145 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Oncology, erschienen am 01.01.2025. Verfasst von Tonny Studsgaard Petersen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cohort study investigates the regulatory fate in the European Union for drugs that received accelerated approval for cancer indications in the US.
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Zitieren
APA
Petersen, T. S., Karstoft, K., Sørup, F. K. H., Lund, M., & Cramer, A. (2025). Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US. JAMA Oncology, 11(1), 70. https://doi.org/10.1001/jamaoncol.2024.5145
Vancouver
Petersen TS, Karstoft K, Sørup FKH, Lund M, Cramer A. Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US. JAMA Oncology. 2025;11(1):70. doi:10.1001/jamaoncol.2024.5145
BibTeX
@article{Petersen2025,
author = {Petersen, Tonny Studsgaard and Karstoft, Kristian and Sørup, Freja Karuna Hemmingsen and Lund, Marie and Cramer, Allan},
title = {Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US},
journal = {JAMA Oncology},
year = {2025},
volume = {11},
number = {1},
pages = {70},
doi = {10.1001/jamaoncol.2024.5145}
}
EUVIMED